의료용 방사성 요오드 I-131 시장 : 세계 예측(2026-2032년)

The Medical Radioactive Iodine I-131 Market is projected to grow by USD 1,025.48 million at a CAGR of 11.82% by 2032.

Medical Radioactive Iodine I-131: Executive Summary

Medical radioactive iodine I-131 is a clinically established radionuclide used primarily in the diagnosis and treatment of thyroid disorders, including differentiated thyroid cancer and hyperthyroidism. Its value chain depends on reactor or accelerator production, radiochemical processing, regulatory authorization, specialized transport, hospital nuclear-medicine infrastructure, and trained clinical personnel. Because I-131 emits both beta and gamma radiation, safe use requires controlled handling, patient-specific dosimetry, radiation protection, and compliant radioactive-waste management.

Supply Resilience and Care Pathways Are Reshaping I-131 Use

The landscape is being transformed by tighter radiation-safety requirements, aging reactor infrastructure, transport constraints, and the need for dependable isotope availability. Healthcare systems are also emphasizing outpatient treatment where clinically appropriate, standardized isolation guidance, digital scheduling, and coordinated endocrinology, oncology, nuclear-medicine, and medical-physics workflows. These changes favor resilient procurement, validated logistics, contingency planning, and consistent clinical protocols rather than reliance on a single production or distribution route.

Artificial Intelligence Strengthens Selection, Scheduling, and Safety

Artificial intelligence can support I-131 care by improving thyroid imaging interpretation, identifying patients who may benefit from radioiodine therapy, assisting dose-planning decisions, and detecting inconsistencies in clinical records. Predictive tools may also help coordinate appointments, isotope delivery, room availability, and follow-up monitoring. However, AI should remain subject to clinician oversight, transparent validation, cybersecurity controls, privacy safeguards, and regulatory review. Its most dependable contribution is decision support integrated with established nuclear-medicine and radiation-protection practices.

Regional Insights: Regulation and Infrastructure Shape Access

North America generally benefits from advanced nuclear-medicine infrastructure, specialist capacity, and mature regulatory systems, while Canada and the United States continue to prioritize reliable isotope logistics and safe outpatient pathways. Europe combines strong clinical expertise with coordinated safety standards, although cross-border transport and differing national procedures require careful planning. Asia-Pacific presents substantial clinical capability alongside uneven access between advanced metropolitan centers and less-resourced areas. Latin America is shaped by concentrated specialist services, import dependence in some settings, and variable infrastructure. The Middle East is expanding specialized healthcare capacity, with access influenced by national investment and cross-border procurement. Africa remains highly heterogeneous, with established services in selected countries and persistent challenges involving equipment, trained staff, isotope logistics, and continuity of care.

Group Insights: Economic and Security Blocs Influence Coordination

ASEAN members face varied nuclear-medicine capacity and may benefit from stronger regional training, referral networks, and coordinated logistics. BRICS countries span major producers, large patient populations, and differing regulatory systems, making interoperability and supply resilience important priorities. The European Union benefits from shared regulatory dialogue while retaining national differences in reimbursement and clinical implementation. G7 countries typically have advanced specialist services but must address aging infrastructure, workforce succession, and continuity during isotope disruptions. GCC states are investing in sophisticated healthcare facilities and may rely on centralized procurement and international expertise. NATO members are relevant to resilience planning because critical infrastructure protection, emergency preparedness, and secure transport can affect medical-isotope continuity.

Country Insights: National Capacity Determines Clinical Continuity

Australia combines specialist nuclear-medicine services with long-distance logistics and geographic concentration. Brazil and Mexico must balance large and diverse patient populations with uneven regional access. Canada and the United States have mature clinical systems but require sustained infrastructure, workforce, and supply-chain resilience. China and India are expanding nuclear-medicine capabilities across broad healthcare geographies, with continued emphasis on quality consistency and specialist training. Japan, South Korea, and Russia maintain substantial technical expertise, while regulatory and logistical continuity remain important. France, Germany, Italy, Spain, and the United Kingdom benefit from established thyroid-care pathways and specialist networks, yet face pressure to modernize facilities and maintain staffing. Across all countries, timely access depends on authorized production, compliant transport, calibrated equipment, trained personnel, and equitable referral pathways.

Action Priorities for Leaders: Secure Supply, Standardize Care, Strengthen Workforce

Industry leaders should diversify qualified isotope sources, establish disruption playbooks, and monitor transport and regulatory dependencies across the full chain. Hospitals should standardize patient selection, informed consent, dosimetry, discharge criteria, contamination controls, and follow-up documentation while adapting protocols to local rules. Investment in medical-physics and nuclear-medicine training is essential, particularly outside major urban centers. Leaders should deploy AI only through clinically validated workflows, maintain human accountability, and audit performance for bias and safety. Partnerships among producers, regulators, hospitals, universities, and referral networks can improve continuity, evidence generation, and equitable access.

Research Methodology: Evidence-Based Assessment of the I-131 Care Ecosystem

This executive summary uses a structured review of the medical radioactive iodine I-131 ecosystem, examining clinical applications, production and processing requirements, regulation, transport, radiation protection, healthcare infrastructure, workforce capability, and digital transformation. Regional, group, and country perspectives are synthesized from publicly documented institutional, governmental, regulatory, and clinical evidence. Interpretations are limited to verifiable structural and operational insights; no market estimates, market sizing, market shares, forecasts, or company-specific claims are included.

Conclusion: Resilience and Clinical Governance Will Define Progress

Medical radioactive iodine I-131 remains an important tool in thyroid disease management, but dependable patient access relies on more than isotope production alone. Resilient supply chains, rigorous radiation safety, coordinated clinical pathways, qualified personnel, modern infrastructure, and responsible use of AI jointly determine outcomes. Leaders that connect these capabilities across national and regional systems will be better positioned to support safe, timely, and equitable I-131 care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Medical Radioactive Iodine I-131 Market, by Product

• 7.1. Introduction
• 7.2. Capsule
• 7.3. Solution

8. Medical Radioactive Iodine I-131 Market, by Application

• 8.1. Introduction
• 8.2. Diagnostic
• 8.3. Therapeutic
  • 8.3.1. Hyperthyroidism
  • 8.3.2. Thyroid Cancer

9. Medical Radioactive Iodine I-131 Market, by End User

• 9.1. Introduction
• 9.2. Clinics
  • 9.2.1. Diagnostic Lab
  • 9.2.2. Outpatient Center
• 9.3. Hospitals
  • 9.3.1. Specialty Cancer Center
  • 9.3.2. Tertiary Care Hospital
• 9.4. Research Institutes
  • 9.4.1. Academic Research Center
  • 9.4.2. Contract Research Organization

10. Medical Radioactive Iodine I-131 Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Online Pharmacy
• 10.3. Hospital Pharmacy
• 10.4. Retail Pharmacy

11. Medical Radioactive Iodine I-131 Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Medical Radioactive Iodine I-131 Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Medical Radioactive Iodine I-131 Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Advanced Biomedicals
• 15.2. Bayer AG
• 15.3. Biodex Medical Systems
• 15.4. Bracco Imaging S.p.A.
• 15.5. CIS Bio International
• 15.6. Curium Pharma
• 15.7. Fujifilm Holdings Corporation
• 15.8. GE Healthcare
• 15.9. IBA Molecular
• 15.10. Isotope Products Laboratories
• 15.11. ITM Isotope Technologies Munich
• 15.12. Jubilant DraxImage Inc.
• 15.13. Lantheus Medical Imaging
• 15.14. Mallinckrodt Pharmaceuticals
• 15.15. Nordion Canada
• 15.16. Nordion Inc.
• 15.17. Nordion Ltd.
• 15.18. PerkinElmer, Inc.
• 15.19. Radiopharm Theranostics
• 15.20. SHINE Medical Technologies
• 15.21. Siemens Healthineers
• 15.22. Sumitomo Heavy Industries, Ltd.

16. Key Experts